Kay M Tomashek
Overview
Explore the profile of Kay M Tomashek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
7048
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rostad C, Yildirim I, Kao C, Yi J, Kamidani S, Peters E, et al.
NPJ Vaccines
. 2024 Dec;
9(1):255.
PMID: 39715748
Filoviruses, including Ebola, Marburg, Sudan, and Taï Forest viruses, are zoonotic pathogens that can cause severe viral hemorrhagic fever and death. Developing vaccines that provide durable, broad immunity against multiple...
2.
Asturias E, Connery A, Olson D, Lamb M, Paniagua-Avila A, Anderson E, et al.
Pediatr Infect Dis J
. 2024 Dec;
44(4):290-298.
PMID: 39637296
Background: Prenatal Zika virus (ZIKV) infection leads to microcephaly and adverse neurodevelopment. The effects of postnatal ZIKV infection on the developing brain are unknown. We assessed the neurodevelopmental outcomes of...
3.
Paules C, Wang J, Tomashek K, Bonnett T, Singh K, Marconi V, et al.
Ann Intern Med
. 2024 Feb;
177(3):343-352.
PMID: 38408357
Background: The ACTT risk profile, which was developed from ACTT-1 (Adaptive COVID-19 Treatment Trial-1), demonstrated that hospitalized patients with COVID-19 in the high-risk quartile (characterized by low absolute lymphocyte count...
4.
Eickhoff C, Meza K, Terry F, Colbert C, Blazevic A, Gutierrez A, et al.
Front Immunol
. 2023 Sep;
14:1247876.
PMID: 37705976
Zika virus (ZIKV) is a flavivirus primarily transmitted by species mosquitoes, first discovered in Africa in 1947, that disseminated through Southeast Asia and the Pacific Islands in the 2000s. The...
5.
Ortega-Villa A, Hynes N, Levine C, Yang K, Wiley Z, Jilg N, et al.
Open Forum Infect Dis
. 2023 Jun;
10(6):ofad290.
PMID: 37383244
Background: Clinical trials initiated during emerging infectious disease outbreaks must quickly enroll participants to identify treatments to reduce morbidity and mortality. This may be at odds with enrolling a representative...
6.
Paulsen G, Frenck Jr R, Tomashek K, Alarcon R, Hensel E, Lowe A, et al.
J Infect Dis
. 2023 Jun;
229(1):30-38.
PMID: 37380156
Background: Andes virus (ANDV), a rodent-borne hantavirus, causes hantavirus pulmonary syndrome (HPS). The safety and immunogenicity of a novel ANDV DNA vaccine was evaluated. Methods: Phase 1, double-blind, dose-escalation trial...
7.
Sweeney D, Tuyishimire B, Ahuja N, Beigel J, Beresnev T, Cantos V, et al.
Open Forum Infect Dis
. 2023 May;
10(5):ofad205.
PMID: 37206623
We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in...
8.
Potter G, Bonnett T, Rubenstein K, Lindholm D, Rapaka R, Doernberg S, et al.
Ann Intern Med
. 2022 Nov;
175(12):1716-1727.
PMID: 36442063
Background: The COVID-19 standard of care (SOC) evolved rapidly during 2020 and 2021, but its cumulative effect over time is unclear. Objective: To evaluate whether recovery and mortality improved as...
9.
Paniagua-Avila A, Olson D, Connery A, Calvimontes D, Bolanos G, Lamb M, et al.
PLoS Negl Trop Dis
. 2022 Nov;
16(11):e0010480.
PMID: 36383617
During the course of the 2015-2017 outbreak of Zika virus (ZIKV) in the Americas, the emerging virus was recognized as a congenital infection that could damage the developing brain. As...
10.
Wang G, Stapleton J, Baker A, Rouphael N, Creech C, El Sahly H, et al.
Open Forum Infect Dis
. 2022 Aug;
9(8):ofac375.
PMID: 35959208
Coinfections are more common in patients with cystic fibrosis and bronchiectasis. Infiltrates on imaging studies are seen more commonly in patients with coinfections, but coinfections did not affect treatment outcomes...